Retinal Deep PhenotypingTM

Sponsor
Optina Diagnostics Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05903651
Collaborator
(none)
4,000
3
17.5
1333.3
76

Study Details

Study Description

Brief Summary

This study aims to collect a baseline dataset of MHRC retinal scans that will be used for the pre-training of deep learning models from the hyperspectral retinal image phenotypic features that may form the basis for multiple future classification applications. A sub-set of the images will also be analyzed by eye specialists to determine if visual inspection of the images could provide useful information in their practice.

As an exploratory study, there are no endpoints per se, however the following sub-objective will be evaluated for determining the success of this study:

  • Collection and characterization of MHRC retinal images from at least 2000 participants that score at least 80 on the real-time Quality Index (included in the MHRC software).

  • Development of at least one (1) DL model of the retina. Models may be used for the development of novel classifier tests and potential use in a clinical setting.

  • At least 5% of participants shall have an MHRC retinal image reviewed by an eye specialist (Optometrist or Ophthalmologist) to assess the image quality and potential clinical usefulness.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is an exploratory, observational, cross-sectional, multi-site study designed to collect a baseline dataset of MHRC retinal image scans for use in Deep Learning models and to determine the feasibility of visual inspection of the images for use in Optometry and/or Ophthalmology clinical practice. Subjects will be recruited from eye clinics where patients will undergo mydriasis (pupil dilation) as part of their clinical visit. Eligible participants will be provided information about the study and delegated site personnel will assist with the Informed Consent process. If a participant provides their Informed Consent, they will be enrolled in the study and undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.

    The MHRC retinal images will be transferred to a Picture Archiving and Communication System (PACS) for archiving and later evaluation. Additional information about the Study Participant will be captured in an Electronic Data Capture (EDC) system, including age, date of birth, gender, race/ethnicity, and color of their iris.

    Images will be transferred to Optina for further digital analysis, including pre-processing (normalization, registration, and segmentation), feature extraction, and inclusion in Deep Learning models.

    A subset (at least 5%) of the MHRC retinal scans will undergo visual inspection by an eye specialist (Ophthalmologist or Optometrist) to determine their quality and utility for inclusion in clinical practice.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    4000 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Retinal Deep PhenotypingTM by a Novel Mydriatic Hyperspectral Retinal Camera (MHRC) and Analysis by Deep Learning
    Actual Study Start Date :
    Feb 13, 2023
    Anticipated Primary Completion Date :
    Jul 31, 2024
    Anticipated Study Completion Date :
    Jul 31, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Single Group Assignment

    The subjects will undergo a single retinal imaging session with the Optina MHRC device, on one or both eyes.

    Outcome Measures

    Primary Outcome Measures

    1. At least one (1) pre-trained DL model from hyperspectral retinal images. [12 months]

    2. Report describing the clinical utility of visual inspection of the MHRC retinal images. [12 months]

    3. Review of any safety events (AE, SAE, UADEs) that occur throughout the study. [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Adults 18 years and older who will undergo mydriasis (pupil dilation) as part of their eye clinic visit.

    Exclusion Criteria:
    • Pupil dilation contraindicated (due to a pathology, or presence of 3 quadrants with Van Herick grading of 0 or 1 without iridotomy).

    • Inadequate pupil dilatation (< 6mm diameter) preventing uniform illumination of the retina with the MHRC.

    • Refractive error outside the range of -15 D to +15 D.

    • Deficient visual fixation (inability to fixate for at least 2 s)

    • Inability of obtaining at least 3 images of satisfactory quality with the MHRC per the Optina Diagnostics quality index software and /or per the eye specialists' evaluation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Waterloo Waterloo Ontario Canada N2L 3G1
    2 Ecole d'Optometrie, University of Montreal Montréal Quebec Canada H3T 1P1
    3 Clinique d'Opthalmologie desLaurentides, Institue de l'Oeil (IOL) Montréal Quebec Canada QC J7H 0E8

    Sponsors and Collaborators

    • Optina Diagnostics Inc.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Optina Diagnostics Inc.
    ClinicalTrials.gov Identifier:
    NCT05903651
    Other Study ID Numbers:
    • 22-002
    First Posted:
    Jun 15, 2023
    Last Update Posted:
    Jun 22, 2023
    Last Verified:
    Jun 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jun 22, 2023